Immunomedics, Seattle Genetics sign $2bn licensing deal for cancer drug
Under an exclusive global licensing agreement, Seattle Genetics will develop, fund, manufacture and commercialize Immunomedics’ solid tumor therapy candidate, IMMU-132. Seattle will also take the responsibility to start
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.